Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study - Isenberg, D A; Petri, M; Kalunian, K (Ann Rheum Dis, 2016)
et al.